Skip to content
Tavneos(avacopan)
Tavneos (avacopan) is a small molecule pharmaceutical. Avacopan was first approved as Tavneos on 2021-10-07. It is used to treat anti-neutrophil cytoplasmic antibody-associated vasculitis in the USA. It has been approved in Europe to treat microscopic polyangiitis and wegener-like granulomatosis. It is known to target C5a anaphylatoxin chemotactic receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Tavneos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avacopan
Tradename
Company
Number
Date
Products
TAVNEOSChemocentryxN-214487 RX2021-10-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
tavneosNew Drug Application2022-02-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anti-neutrophil cytoplasmic antibody-associated vasculitis—D056648I77.82
Agency Specific
FDA
EMA
Expiration
Code
AVACOPAN, TAVNEOS, CHEMOCENTRYX
2028-10-07ODE-377
2026-10-07NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Avacopan, Tavneos, Chemocentryx
116033562041-05-29DS, DPU-3558
84455152031-02-03DS, DP
89069382029-12-21DS, DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anti-neutrophil cytoplasmic antibody-associated vasculitisD056648I77.82—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VasculitisD014657EFO_0006803M31—1———1
GlomerulonephritisD005921N05—1———1
Hidradenitis suppurativaD017497L73.2—1———1
Atypical hemolytic uremic syndromeD065766—1———1
Iga glomerulonephritisD005922EFO_0004194—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAVACOPAN
INNavacopan
Description
Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.
Classification
Small molecule
Drug classcomplement receptor antagonists/complement inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F
Identifiers
PDB—
CAS-ID1346623-17-3
RxCUI—
ChEMBL IDCHEMBL3989871
ChEBI ID—
PubChem CID49841217
DrugBankDB15011
UNII IDO880NM097T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
C5AR1
C5AR1
Organism
Homo sapiens
Gene name
C5AR1
Gene synonyms
C5AR, C5R1
NCBI Gene ID
728
Protein name
C5a anaphylatoxin chemotactic receptor 1
Protein synonyms
C5a anaphylatoxin chemotactic receptor, C5a anaphylatoxin receptor, C5a ligand, C5a-R, C5aR, CD88, complement component 5a receptor 1
Uniprot ID
P21730
Mouse ortholog
C5ar1 (12273)
C5a anaphylatoxin chemotactic receptor 1 (Q3TZ86)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 380 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details